Agilent Technologies — Executive summary (facts from FY2025 Form 10‑K)

Company overview

• Agilent Technologies, Inc. is a global provider of instruments, software, services and consumables for life sciences, diagnostics and applied markets.
• Fiscal year referenced: year ended October 31, 2025.
• Corporate headquarters: 5301 Stevens Creek Blvd., Santa Clara, California.

Organizational structure (post-November 2024 reorganization)

• The company reorganized in November 2024 into three reportable business segments (historical results were recast to this presentation):
  • Life Sciences and Diagnostics Markets
  • Agilent CrossLab
  • Applied Markets

What the company sells (selected specifics by capability)

• Instruments and analytical platforms:

  • Liquid chromatography (LC), ultra-high performance LC
  • Liquid chromatography–mass spectrometry (LC‑MS)
  • Gas chromatography (GC) and GC–MS
  • Mass spectrometry families (single quad, triple quad, TOF, Q‑TOF)
  • Inductively coupled plasma (ICP‑MS, ICP‑OES), atomic absorption, microwave plasma‑AES
  • Spectroscopy: FTIR, near‑IR, Raman, UV‑Vis, fluorescence
  • Vacuum technology and leak‑detection equipment
  • Cell analysis platforms (flow cytometers, live‑cell analyzers), microplate readers, imaging
  • Pathology / tissue staining and immunohistochemistry platforms and reagents
  • Genomics consumables and target enrichment products; arrays for comparative genomic hybridization
  • Automated electrophoresis and biomolecular quality‑control tools
  • Remarketed / refurbished instruments

• Consumables, reagents and lab supplies:

  • LC/GC columns, sample preparation products (SPE, filtration), standards, OEM parts, specialty chemistries, antibodies and clinical flow cytometry reagents

• Services, software and automation:

  • Instrument service, maintenance contracts, repairs, compliance and installation
  • Laboratory informatics (OpenLab software suite), Software‑as‑a‑Service, asset management
  • Laboratory automation (liquid handling, plate management, scheduling)

• Contract development & manufacturing organization (CDMO):

  • Nucleic‑acid/oligonucleotide active pharmaceutical ingredient production and clinical‑to‑commercial biomanufacturing capabilities (including BIOVECTRA capabilities).

Key end markets (examples)

• Pharmaceutical and biopharmaceutical companies (small molecules and biologics, cell & gene therapies)
• Diagnostics and clinical laboratories (hospital, reference labs, high‑complexity clinical labs)
• Academic and government research institutions
• Chemicals and advanced materials (including semiconductors, batteries, polymers)
• Food safety and testing
• Environmental testing and forensics
• OEMs for vacuum and scientific equipment

Customers and employees (FY2025)

• Employees (global): approximately 18,100 as of October 31, 2025.
  • Life Sciences & Diagnostics Markets employees: ~6,300
  • Agilent CrossLab employees: ~7,400
  • Applied Markets employees: ~2,500
  • Global infrastructure organization: ~1,900
• Reported customers (FY2025), by segment:
  • Life Sciences and Diagnostics Markets: ~22,200 customers
  • Agilent CrossLab: ~59,700 customers
  • Applied Markets: ~17,200 customers

Financial highlights (FY2025)

• Net revenue: $6,948 million (FY2025)
  • Products revenue: $4,944 million
  • Services & other revenue: $2,004 million
• Revenue by segment (FY2025):
  • Life Sciences & Diagnostics Markets: $2,726 million
  • Agilent CrossLab: $2,908 million
  • Applied Markets: $1,314 million
• Net income (GAAP): $1,303 million (FY2025)
• Cash and cash equivalents: $1,789 million (as of October 31, 2025)

Other notable reported facts

• BIOVECTRA (CDMO) acquisition contributed to 2025 revenue (company estimated contribution: ~2 percentage points to consolidated 2025 growth; ~5 percentage points within the Life Sciences & Diagnostics Markets segment).
• Shares outstanding: 283,498,871 shares (as of December 10, 2025).
• Aggregate market value of common equity held by non‑affiliates: approximately $26.6 billion (as of April 30, 2025).
• Manufacturing / R&D footprint: primary sites in the U.S. (California, Colorado, Delaware, Massachusetts, Texas, Vermont) and facilities in Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom. Several sites are FDA‑registered.

(End of summary — all items above are drawn directly from the provided Form 10‑K text for the year ended October 31, 2025.)